Last reviewed · How we verify

Filsuvez — Competitive Intelligence Brief

Filsuvez (garadacimab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-Factor XIIa monoclonal antibody. Area: Hematology.

marketed Anti-Factor XIIa monoclonal antibody Activated Factor XII (FXIIa) Hematology Biologic Live · refreshed every 30 min

Target snapshot

Filsuvez (garadacimab) — CSL Behring. Monoclonal antibody that inhibits activated Factor XII (FXIIa), preventing the generation of bradykinin which causes angioedema attacks.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Filsuvez TARGET garadacimab CSL Behring marketed Anti-Factor XIIa monoclonal antibody Activated Factor XII (FXIIa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-Factor XIIa monoclonal antibody class)

  1. CSL Behring · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Filsuvez — Competitive Intelligence Brief. https://druglandscape.com/ci/garadacimab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: